a public good project by the
Synthesis
Company
of California

© 2026

Richard T. Maziarz | doi.page

0 works0 citations0 h-index

Richard T. Maziarz

Oregon Health & Science University(US)OHSU Knight Cancer Institute

Publications by Year

Research Areas

Hematopoietic Stem Cell Transplantation, CAR-T cell therapy research, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments

Most-Cited Works

→ Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma(2018)3,936 cited
→ Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma(2012)1,139 cited
→ Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation(2014)920 cited
→ Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors(2012)889 cited
→ Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients(2005)793 cited
→ Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma(2009)775 cited

→ Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma(2009)670 cited

→ Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes(2017)652 cited

→ Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study(2021)537 cited

→ Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma(2021)500 cited